Research in contextEvidence before this studyWe searched PubMed for articles up to May 23, 2020, using the keywords \'2019 novel coronavirus\', \'COVID-19′, \'SARS-CoV-2′, and \'coronavirus\' for articles published without any language restrictions. We found that the mortality of critically ill COVID-19 patients is significantly greater than that of severely and moderately ill patients. However, risk factors of developing critical COVID-19 remain enigmas, especially their difference between sexes.Added value of this studyWe found that the clinical features and course of COVID-19 were similar between moderate and severe group, but critical patients have dramatically distinct features. We revealed risk factors of developing critical COVID-19 differ between sexes, where hypertension and CHD remarkably increased the risk of critical disease in male, but barely affected female patients.Implications of all the available evidenceThese results highlight the significance of dividing risk factors between sexes in clinical and epidemiologic works of COVID-19, and perhaps other coronavirus appearing in future.Alt-text: Unlabelled box

1. Introduction {#sec0001}
===============

From December 2019, a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), outbroke in Wuhan, China and ferociously spread around the world, causing major public health emergency of global concern. The WHO named the pneumonia caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19) [@bib0001], which has begun behaving greatly like a once-in-a-century pandemic [@bib0002]. As of June 18, 2020, there have been 8242,999 confirmed cases of COVID-19, including 445,535 deaths, reported to WHO globally [@bib0003].

Though clinical characteristics and risk factors for mortality of COVID-19 have been portrayed [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], we feel the necessity to delineate them more comprehensively. Available clinical information well reflected the early stage of COVID-19 outbreak, but witnessed limited patients with definite outcomes. Clinical data that depict the peak of the pandemic and document the clinical course from admission to discharge or death will contribute to better understanding of progression and remission of COVID-19. Moreover, mortality of critically ill patients is 49.0%, by contrast with 2.3% for overall COVID-19 patients [@bib0005]. unraveling risk factors associated with developing into critical illness will facilitate early identification of high-risk patients.

Here, we provide detailed clinical information of COVID-19 patients admitted to two branches of Tongji Hospital, the unique designed hospital for severely and critically ill patients in Wuhan and the epicenter of COVID-19 pandemic, where 40 first-class medical teams from 13 provinces cooperated and engaged with COVID-19 at the peak of COVID-19 crisis in China. We aim to delineate comprehensive features of COVID-19 patients with known outcomes (death or discharge) as of March 21, 2020 and explore risk factors accounting for developing into severe/critical illness.

2. Methods {#sec0002}
==========

2.1. Study design and participants {#sec0003}
----------------------------------

This study was carried out in two branches of Tongji hospital (Optical Valley Branch and Sino-French New City Branch), which were reinvented imminently and designated at the peak of outbreak in Wuhan to receive moderate, severe, and critical COVID-19 patients. 40 medical teams from 13 provinces worked here simultaneously, each of whom in charge of one ward unit independently with slightly different therapeutic regimen, making this study as a mini-national multi-center study. In this retrospective cohort study, we included 2387 consecutive patients that underwent discharge or death between January 27 (the admission date of the first COVID-19 patients) and March 21, 2020 (the beginning of transferring patients to other hospitals). We believe that this study period could best reflect the outbreak period of the disease and best eliminate potential bias.

72 patients failed to meet diagnostic criteria and were excluded according to Guidance for COVID-19 (7th edition) released by the National Health Commission of China [@bib0010]. We further excluded 205 patients transferred from mobile cabin hospitals for isolation, 31 patients died within 24 hrs of admission lacking blood test and medical history, and 35 patients with ages of less than 18, pregnant, re-hospitalization or discharge for special reasons such as dialysis. Finally, 2044 patients were included, with 1741 laboratory-confirmed and 303 clinically-diagnosed cases (before antibody tests were available) according to Guidance for COVID-19 (5th edition) released by the National Health Commission of China [@bib0011]. The flowchart of the study is shown in [Fig. 1](#fig0001){ref-type="fig"} . The study was approved by the Medical Ethical Committee of Tongji Hospital (TJIRB20200406) with written informed consent waived. The trial has been registered in Chinese Clinical Trial Registry (ChiCTR2000032161).Fig. 1the flowchart of this study.Fig. 1:

2.2. Data collection and oversight {#sec0004}
----------------------------------

Epidemiological, demographic, laboratory, radiological, treatment, nursing, and outcome data were obtained from electronic medical record using a designed data collection form. Experienced clinicians from Tongji Hospital analyzed patients' medical records. Trained and experienced researchers entered and double-checked data in a computerized database. All authors reviewed the manuscript and guarantee the accuracy and completeness of the data.

2.3. Laboratory procedures and treatment {#sec0005}
----------------------------------------

Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay for SARS-CoV-2 is interpreted elsewhere \[[@bib0012],[@bib0013]\]. Briefly, RT-PCR testing was used according to the recommended protocol [@bib0012]. The primers and probes for SARS-CoV-2 detection were selected according to the National Pathogen Resource Center (National Institute for Viral Disease Control and Prevention, China CDC) [@bib0012]. Serum quantitative and qualitative SARS-CoV-2 IgM and IgG antibodies were detected using commercial chemiluminescence kit (iFlash-SARS-CoV-2 IgM (Cat. No. C86095M), iFlash-SARS-CoV-2 IgG (Cat. No. C86095G), SHENZHEN YHLO BIOTECH CO., LTD.). Blood tests, radiology (Chest radiographs or CT scan) were performed on admission, and the time point of re-examinations and treatments were determined by physicians according to guidance aforementioned and individual differences.

2.4. Criteria of COVID-19 severity {#sec0006}
----------------------------------

COVID-19 severity of each patient was classified based on the most severe condition during the entire course of the disease. According to the Guidance for Coronavirus Disease 2019 (7th edition) released by the National Health Commission of China [@bib0010], COVID-19 was diagnosed and divided into four groups (mild, moderate, severe and critical) \[[@bib0012],[@bib0014]\]. In mild group, the symptoms are mild and had no abnormal radiological findings. For the three groups involved in our study, patients in moderate group have symptoms including fever and respiratory tract symptoms, and an imaging finding of pneumonia, but fails to meet the criteria for severe group and critical group. COVID-19 patients that meet any of the following criteria belong to severe group: 1) dyspnea or respiratory rate ≥ 30 breaths/min; 2) SPO~2~ ≤ 93•00% at a rest state; 3) arterial partial pressure of oxygen (PaO~2~)/oxygen concentration (FiO~2~) ≤ 300 mmHg; 4) patients with \> 50.00% lesion progression in lung imaging within 48 hrs. Critical group is defined as patients that meet any of the following criteria: 1) presence of respiratory failure and mechanical ventilation is required; 2) occurrence of shock; 3) complicated with other organ failure that requires admission to ICU.

2.5. Definitions {#sec0007}
----------------

Fever was defined as axillary temperature ≥ 37.30 °C (high fever ≥ 39.00 °C). Illness onset referred to the appearance of pneumonia-related symptoms, such as fever, cough, dyspnea, etc. Number of comorbidities was referred to the number of different complications including hypertension, diabetes, coronary heart disease (CHD), chronic liver disease (CLD), chronic kidney disease (CKD) and chronic obstructive pulmonary disease (COPD). Sepsis and septic shock were defined according to the 2016 Third International Consensus Definition for Sepsis and Septic Shock [@bib0013]. Secondary infection was diagnosed when patient had a positive culture of a new pathogen obtained from lower respiratory tract specimens (qualified sputum, endotracheal aspirate, or bronchoalveolar lavage fluid) or blood samples after admission. Acute kidney injury was diagnosed according to the KDIGO guidelines [@bib0015]. Acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin Definition [@bib0016]. Acute cardiac injury was diagnosed if serum level of cardiac troponin I was above the 99th percentile upper reference limit. Coagulopathy was defined as a 3-second extension of prothrombin time (PT) or a 10-second extension of activated partial thromboplastin time (APTT). Hypoproteinaemia was defined as serum level albumin ≤ 30 g/L. Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score was referred to previous reported [@bib0013]. Acute heart failure was diagnosed with typical symptoms (e.g. breathlessness) and accompanied signs (e.g. elevated jugular venous pressure) caused by a cardiac abnormality [@bib0017]. Acute liver injury was defined as serum level of total bilirubin ≥ 3 mg/dl and an acute increase in ALT of at least five times the upper limit of the normal range and/or an increase in alkaline phosphatase of at least twice the upper limit of the normal [@bib0012].

2.6. Statistical analysis {#sec0008}
-------------------------

Continuous variables were expressed as medians and interquartile ranges (IQR). Categorical variables were summarized as n (%) in each category. Kruskal-Wallis test, chi-square test, and Fisher\'s exact test were applied where appropriate. Uni- and multivariable binary logistic regression were used to explore the risk factors. Dyspnea and laboratory indexes were excluded from regression analysis, as they were considered to be reflections of disease severity. Any variable with *P* \< 0•25 in univariate analysis was included in the model building of multivariable logistic regression, and then a backward elimination strategy was used to delete variables that contribute the least until the final model. The odds ratio (OR) along with the 95% confidence interval (95% CI) was reported. Variables with no differences, too small to analysis odds ratios, and colinear with the severity of disease were excluded from analysis. The effect modification between sexes and other factors were tested using logistic regression models containing the interaction terms (sex and hypertension, etc.). The missing data of demographics, clinical, laboratory and radiological characteristics were dealt as missing values, while there were limited missing data in logistic regression analysis (2041 records of symptoms and 2039 records of comorbidities). A two-sided *P* value of less than 0•05 was considered statistically significant. Statistical analyses were done using the STATA software (version 15.1).

2.7. Role of funding source {#sec0009}
---------------------------

The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (QLG) had full access to all data in the study and final responsibility for the study.

3. Results {#sec0010}
==========

3.1. Demographics and characteristics in different severity of COVID-19 patients {#sec0011}
--------------------------------------------------------------------------------

Demographics and characteristics of COVID-19 patients are provided in [Table 1](#tbl0001){ref-type="table"} . Exact cases in charge by each medical team are shown in [Fig. 2](#fig0002){ref-type="fig"} . Among 2044 patients, there were 1087 (53%) moderate, 689 (34%) severe, and 268 (13%) critical cases. The median age of critical group (69•0, IQR: 62•0--77•0) was significantly greater (*P* = 0•001) than that of severe group (64•0, IQR: 54•0--71•0) and moderate group (59.0, IQR: 46•0--67•0). 80•22% of patients in critical group was aged ≥ 60, by contrast with 61.54% for severe group and 49•49% for moderate group. Generally, 57•63% of all patients and 79•7% of critical group had at least one comorbidity. Critical group witnessed more comorbidities (hypertension, 56•02%; diabetes, 22•56%; coronary heart disease (CHD), 17•29%; chronic kidney disease (CKD), 3•01%; tumor, 7•14%; chronic obstructive pulmonary disease (COPD), 3•01%). For symptoms, fever was the most prevalent symptom in all patients (80•55%). Cough, dyspnea, and disorders of consciousness were more prevalent in critical group.Table 1Characteristics of patients with different disease severity of COVID-19 on admission.Table 1Disease severityTotal (*n* = 2044)Moderate (*n* = 1087)Severe (*n* = 689)Critical (*n* = 268)*p* valueAge, years62•0 (51•0--70•0)59•0 (46•0--67•0)64•0 (54•0--71•0)69•0 (62•0--77•0)0•0001≥601177 (57•58%)538 (49•49%)424 (61•54%)215 (80•22%)\<0•001Sex‥‥‥‥\<0•001 Female1044 (51•08%)612 (56•30%)340 (49•35%)92 (34•33%)‥ Male1000 (48•92%)475 (43•70%)349 (50•65%)176 (65•67%)‥Presence of comorbidity1175/2039 (57•63%)540/1086 (49•72%)423/687 (61•57%)212/266 (79•70%)\<0•001 Hypertension810/2039 (39•73%)3567/1086 (32•87%)304/687 (44•25%)149/266 (56•02%)\<0•001 Diabetes341/2039 (16•72%)140/1086 (12•89%)141/687 (20•52%)60/266 (22•56%)\<0•001 CHD199/2039 (9•76%)79/1086 (7•27%)74/687 (10•77%)46/266 (17•29%)\<0•001 CLD78/2041 (3•82%)44/1086 (4•05%)22 (3•19%)12/266 (4•51%)0•538 Tumor63/2039 (3•09%)25/1086 (2•30%)19/687 (2•77%)19/266 (7•14%)\<0•001 CKD32/2039 (1•57%)14/1086 (1•29%)10/687 (1•46%)8/266 (3•01%)0•124 COPD18/2039 (0•88%)3/1086 (0•28%)7/687 (1•02%)8/266 (3•01%)\<0•001Number of comorbidities1•0 (0•0--2•0)1•0 (0•0--1•0)1•0 (0•0--2•0)1•0 (1•0--2•0)0•0001Temperature, °C38•3 (37•5--39•0)38•0 (37•2--38•9)38•5 (37•8--39•0)38•3 (37•8--38•9)0•0001 Fever ≥37•01644/2041 (80•55%)834/1086 (76•80%)589/688 (85•61%)221/267 (82•77%)\<0•001 High fever ≥39•0521/2027 (25•70%)243/1077 (22•56%)213/688 (30•96%)65/262 (24•81%)\<0•001Cough1487/2041 (72•86%)755/1086 (69•52%)517/688 (75•15%)215/267 (80•52%)\<0•001Dyspnea870/2041 (42•63%)351/1086 (32•32%)338/688 (49•13%)181/267 (67•79%)\<0•001Sputum805/2041 (39•44%)388/1086 (35•73%)302/688 (43•90%)115/267 (43•07%)0•001Fatigue736/2041 (36•06%)370/1086 (34•07%)258/688 (37•50%)108/267 (40•45%)0•095Diarrhea488/2041 (23•91%)231/1086 (21•27%)195/688 (28•34%)62/267 (23•22%)0•003Myalgia406/2041 (19•89%)227/1086 (20•90%)131/688 (19•04%)48/267 (17•98%)0•444Vomiting93/2041 (4•56%)46/1086 (4•24%)35/688 (5•09%)12/267 (4•49%)0•703Disorders of consciousness at admission63 (3•08%)4 (0•37%)6 (0•87%)53 (19•78%)\<0•001Respiratory rate, per min21•0 (20•0--24•0)20•0 (20•0--22•0)22•0 (20•0--24•0)29•0 (22•0--33•0)0•0001 ≥24525/2039 (25•75%)117/1086 (10•77%)223 (32•37%)185/264 (70•08%)\<0•001Mean arterial pressure, mmHg96•7 (88•7--105•7)96•7 (88•7--105•7)96•0 (88•7--105•0)97•0 (89•7--106•7)0•4391 \<7020/2041 (0•98%)6/1085 (0•55%)6/688 (0•87%)8 (2•99%)0•001SpO2,%95•0 (92•0--97•0)96•0 (95•0--98•0)92•0 (90•0--95•0)86•0 (76•0--92•0)0•0001 ≤93562/2038 (27•58%)0/1084 (0•00%)352/687 (51•24%)210/267 (78•65%)\<0•001SOFA score at admission1•0 (0•0--2•0)0•0 (0•0--0•0)1•0 (1•0--2•0)5•0 (3•5--6•5)0•0001 0--1594/1211 (49•05%)177/255 (69•41%)416/688 (60•47%)1/268 (0•37%)\<0•001 2--3372/1211 (30•72%)69/255 (27•06%)237/688 (34•45%)66 /268(24•63%)‥ ≥4245/1211 (20•23%)9/255 (3•53%)35/688 (5•09%)201/268 (75•00%)‥Time from illness onset to hospital visit, days6•0 (3•0--11•0)7•0 (3•0--12•0)6•0 (3•0--9•0)5•0 (2•0--9•0)0•0001Time from illness onset to hospital admission, days12•0 (8•0--18•0)13•0 (8•0--20•0)11•0 (8•0--16•0)11•0 (7•0--16•0)0•0001Laboratory findingsWhite blood cell count, × 10^9^ per L5•7 (4•4--7•4)5•3 (4•2--6•7)5•6 (4•5--7•2)9•1 (6•3--12•9)0•0001 \>10192/2042 (9•40%)28/1086 (2•58%)50 (7•26%)114/267 (42•70%)\<0•001Lymphocyte count, × 10^9^ per L1•1 (0•8--1•6)1•4 (1•0--1•8)1•0 (0•7--1•4)0•6 (0•4--0•8)0•0001 \<0•8555/2041 (27•19%)154/1085 (14•19%)214 (31•06%)187/267 (70•04%)\<0•001Hemoglobin, g/L126•0 (116•0--137•0)126•0 (116•0--137•0)126•0 (116•0--136•0)128•0 (115•0--143•0)0•3030Anemia392/2041 (19•21%)193/1085 (17•79%)132 (19•16%)67/267 (25•09%)0•025Platelet count, × 10^9^ per L222•0 (167•0--291•5)229•0 (179•5--297•0)225•0 (170•0--296•0)165•5 (117•0--235•0)0•0001 \<10096/2036 (4•72%)28/1084 (2•58%)18/686 (2•62%)50/266 (18•80%)\<0•001Alanine aminotransferase, U/L22•0 (14•5--37•0)20•0 (14•0--34•0)24•0 (15•0--41•0)27•5 (18•0--43•0)0•0001 \>40446 (21•82%)198 (18•22%)173 (25•11%)75 (27•99%)\<0•001Aspartate aminotransferase, U/L25•0 (19•0--38•0)22•0 (18•0--31•0)28•0 (20•0--41•0)39•0 (27•5--59•0)0•0001 \>40430/2036 (21•12%)130/1083 (12•00%)173/685 (25•26%)127 (47•39%)\<0•001Albumin, g/L35•5 (32•0--39•4)37•5 (34•3--40•9)34•2 (31•3--37•6)31•0 (27•9--34•0)0•0001 ≤30292/2041 (14•31%)64/1085 (5•90%)113/688 (16•42%)115 (42•91%)\<0•001Total bilirubin, μmol/L8•7 (6•5--12•1)8•0 (6•1--10•8)8•9 (6•6--12•3)12•1 (8•5--17•5)0•0001 ≥2097/2041 (4•75%)20/1085 (1•84%)30/688 (4•36%)47 (17•54%)\<0•001Lactate dehydrogenase, U/L262•0 (203•0--351•0)224•0 (187•0--283•0)290•0 (232•0--374•0)480•5 (371•0--634•0)0•0001 ≥2451156/2038 (56•72%)426/1086 (39•23%)478/686 (69•68%)252/266 (94•74%)\<0•001Blood urea nitrogen, mmol/L4•4 (3•4--5•8)4•1 (3•3--5•1)4•3 (3•3--5•5)8•0 (5•5--12•1)0•0001 ≥10144 (7•05%)20 (1•84%)31 (4•50%)93 (34•70%)\<0•001Creatinine, μmol/L68•0 (57•0--85•0)65•0 (56•0--80•0)69•0 (57•0--85•0)83•0 (66•0--109•0)0•0001 ≥110161 (7•88%)47 (4•32%)49 (7•11%)65 (24•25%)\<0•001Uric acid, μmol/L255•3 (196•2--332•0)259•0 (206•0--325•0)245•0 (187•0--309•0)263•0 (184•5--363•0)0•0006Prothrombin time, s13•8 (13•3--14•5)13•6 (13•1--14•1)13•9 (13•3--14•5)15•1 (14•1--16•6)0•0001 ≥1775/2007 (3•74%)9/1062 (0•85%)10/680 (1•47%)56/265 (21•13%)\<0•001Activated partial thromboplastin time, s38•8 (35•8--42•7)38•4 (35•7--41•9)39•3 (36•3--43•5)39•7 (35•9--45•4)0•0001 ≥5276/1839 (4•13%)23/994 (2•31%)24/615 (3•90%)29/230 (12•61%)\<0•001D-dimer, μg/mL0•73 (0•35--1•74)0•47 (0•26--1•05)0•89 (0•48--1•81)4•16 (1•39--21•00)0•0001 \>1794/1969 (40•33%)274/1046 (26•20%)307/668 (45•96%)213/255 (83•53%)\<0•001High-sensitivity cardiac troponin I, pg/mL4•4 (1•9--10•6)2•7 (1•9--5•9)5•0 (2•5--11•7)29•1 (9•1--175•2)0•0001 Male\>34•2\
 Female\>15•6244/1725 (14•14%)40/914 (4•38%)68/584 (11•64%)136/227 (59•91%)\<0•001NT-proBNP, pg/mL119•0 (44•5--353•0)67•0 (29•0--169•0)146•0 (62•0--370•0)768•0 (291•5--2186•5)0•0001 \>450330/1608 (20•52%)63/821 (7•67%)116/555 (20•90%)151/232 (65•09%)\<0•001C reactive protein, mg/L17•2 (2•5--64•8)5•1 (1•2--26•5)34•4 (6•6--79•6)98•2 (59•3--151•9)0•0001 \>101110/1936 (57•33%)404/1022 (39•53%)467/661 (70•65%)239/253 (94•47%)\<0•001Erythrocyte sedimentation rate, mm/h32•0 (15•0--58•5)24•0 (11•0--47•0)40•0 (22•0--65•0)40•0 (22•0--67•0)0•0001Ferritin, ug/L554•7 (313•8--1067•3)421•5 (229•5--619•8)634•9 (354•1--1134•4)1353•2 (798•0--2162•4)0•0001 \>600535/1159 (46•16%)155/561 (27•63%)219/407 (53•81%)161/191 (84•29%)\<0•001Procalcitonin, ng/mL0•06 (0•04--0•11)0•05 (0•03--0•06)0•06 (0•04--0•12)0•21 (0•11--0•67)0•0001 ≥0•25219/1749 (12•52%)28/896 (3•13%)71/595 (11•93%)120/258 (46•51%)\<0•001IL-2R570•0 (363•0--871•0)469•0 (318•0--673•0)615•0 (412•0--909•0)1098•0 (768•0--1565•0)0•0001 \>710589/1654 (35•61%)186/862 (21•58%)234/577 (40•55%)169/215 (78•60%)\<0•001IL-6, pg/mL5•4 (2•0--22•5)3•3 (1•5--8•7)7•4 (2•6--26•4)54•9 (22•0--137•1)0•0001 ≥7750/1663 (45•10%)257/870 (29•54%)295/578 (51•04%)198/215 (92•09%)\<0•001 ≥14547/1663 (32•89%)156/870 (17•93%)213/578 (36•85%)178/215 (82•79%)\<0•001IL-810•7 (6•1--20•9)9•0 (5•6--15•8)10•8 (6•4--20•3)25•7 (13•8--55•5)0•0001 ≥62110/1653 (6•65%)34/862 (3•94%)29/576 (5•03%)47/215 (21•86%)\<0•001IL-105•0 (5•0--5•7)5•0 (5•0--5•0)5•0 (5•0--5•6)8•6 (5•0--14•9)0•0001TNF-α7•7 (5•8--10•3)7•2 (5•4--9•2)8•3 (5•9--10•8)11•1 (7•4--15•5)0•0001 ≥8•1762/1651 (46•15%)310/862 (35•96%)299/575 (52•00%)153/214 (71•50%)\<0•001Radiologic findingsBilateral pulmonary infiltration1833/1981 (92•53%)960/1077 (89•14%)655/680 (96•32%)218/224 (97•32%)\<0•001Ground-glass opacity1030/1903 (54•13%)557/1066 (52•25%)381/676 (56•36%)92/161 (57•14%)0•177[^2]Fig. 2Medical teams supporting Wuhan and the number of patients they are in charge in two branches of Tongji Hospital.OVB=Optical Valley Branch, SFNCB= Sino-French New City Branch, TJ= Tongji.Fig. 2:

Vital signs were also recorded for all patients. More patients in critical group experienced the Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score ≥ 4 at admission than those in severe group and moderate group (critical vs. severe vs. moderate: 75•00% vs. 5•09% vs. 3•53%). The median time from illness onset to hospital visit and from illness onset to hospital admission were both shorter (*P* = 0•001; *P* = 0•001) in severe (6•0, IQR: 3•0--9•0; 11•0, IQR: 8•0--16•0) /critical (5•0, IQR: 2•0--9•0; 11•0, IQR: 7•0--16•0) groups than in moderate group (7•0, IQR: 3•0--12•0; 13•0, IQR: 8•0--20•0).

3.2. Laboratory and radiological findings {#sec0012}
-----------------------------------------

We observed substantial differences in laboratory findings among patients in three groups ([Table 1](#tbl0001){ref-type="table"}). Leukocytosis, lymphopenia, thrombocytopenia, hyperbilirubinemia, and hypoalbuminemia were more commonly seen in critical group than severe group and moderate group. Significantly increased PT (*P* = 0•001), APTT (*P* = 0•001), cTnI (*P* = 0•001), NT-proBNP (*P* = 0•001), ferritin (*P* = 0•001), and procalcitonin (*P* = 0•001) were observed in critical group when compared with severe group and moderate group. For radiologic findings, we observed comparable ground glass opacity between three groups, more bilateral pulmonary infiltration in severe/critical groups than moderate group, and more consolidation in severe group than moderate and critical group.

Additionally, serum levels of IL-2R, IL-6, IL-8, IL-10, and TNF-α were prominently higher in critical group on admission ([Table 1](#tbl0001){ref-type="table"}). Several pivotal laboratory indicators IL-6, CRP, [d]{.smallcaps}-dimer, leukocyte count, and cTnI were significantly higher, whereas lymphocyte counts were lower in critical group than severe group and moderate group, with *P* \< 0•05 for all time points shown throughout the clinical course ([Fig. 3](#fig0003){ref-type="fig"} ). In severe group and moderate group, most of the index were mildly abnormal and were restored to the normal range at the 3rd week after illness onset. In critical group, [d]{.smallcaps}-dimer, cTnI, and leukocyte increased to the peak at 2--3 weeks after illness onset and then decreased, while IL-6, IL-8, and TNF-α were consistently elevated at high levels and were continued to rise for as long as five weeks ([Fig. 3](#fig0003){ref-type="fig"} and Supplementary Figure 1).Fig. 3Dynamic changes in laboratory markers from illness onset in patients with COVID-19.Figure shows temporal changes in the median and IQR of interleukin-6 (A), high-sensitivity C-reactive protein (B), leukocyte count (C), lymphocyte count (D), D-dimer (E), and high-sensitivity cardiac troponin I (F). The overall differences among moderate, severe and critical group were significant for all timepoints shown. COVID-19=coronavirus disease 2019.Fig. 3:

3.3. Treatments and outcomes of patients with different disease severity {#sec0013}
------------------------------------------------------------------------

Critical group received significantly fewer (*P* \< 0•001) antiviral treatments, while more (*P* \< 0•001) antibiotics compared with severe group and moderate group though lopinavir/ritonavir and ribavirin therapy were comparable in three groups ([Table 2](#tbl0002){ref-type="table"} ). Critical group tended to receive more interferon, glucocorticoid, and intravenous immunoglobin therapy. The duration of using all antiviral treatments, interferon, and glucocorticoid were shorter in critical group. Notably, critical group harbored a higher possibility of receiving non-invasive and invasive mechanical ventilation or ECMO than severe group and moderate group (critical vs. severe vs. moderate; non-invasive: 43•66% vs. 0•00% vs. 0•00%; invasive: 47•76% vs. 0•16% vs. 0•00%).Table 2Treatments and outcomes of patients with different disease severityTable 2Disease severityTotal (*n* = 2044)Moderate (*n* = 1087)Severe (*n* = 689)Critical (*n* = 268)*p* valueTreatmentsAntibiotics1618/2043 (79•20%)782 (71•94%)577 (83•74%)259/267 (97•00%)\<0•001 Carbostyrl1469/2043 (71•90%)728 (66•97%)527 (76•49%)214/267 (80•15%)\<0•001 Cephalosporin463/2043 (22•66%)162 (14•90%)166 (24•09%)135/267 (50•56%)\<0•001 Broad-spectrum antibiotics233/2043 (11•40%)40 (3•68%)43 (6•24%)150/267 (56•18%)\<0•001Antiviral treatments1892 (92•56%)1022 (94•02%)650 (94•34%)220 (82•09%)\<0•001 Arbidol hydrochloride1653 (80•87%)916 (84•27%)569 (82•58%)168 (62•69%)\<0•001 Duration of use, days9•0 (6•0--12•0)9•0 (7•0--13•0)10•0 (6•0--12•0)5•0 (3•0--7•0)0•0001 Oseltamivir605 (29•60%)354 (32•57%)202 (29•32%)49 (18•28%)\<0•001 Duration of use, days6•0 (3•0--10•0)6•0 (4•0--10•0)6•0 (4•0--10•0)5•0 (2•0--7•0)0•0086 Lopinavir/ritonavir422 (20•71%)216 (19•91%)159 (23•14%)47 (17•67%)0•111 Duration of use, days8•0 (4•0--11•0)7•0 (4•0--10•0)9•0 (6•0--11•0)5•0 (2•0--9•0)0•0001 Ribavirin191 (9•34%)98 (9•02%)60 (8•71%)33 (12•31%)0•196  Duration of use, days5•0 (0•5--8•0)5•0 (0•0--8•0)5•0 (3•0--10•0)3•0 (1•5--4•5)0•0298 Interferon215 (10•53%)107 (9•85%)68 (9•88%)40 (14•93%)0•042  Duration of use, days3•0 (1•0--7•0)3•5 (1•0--7•0)3•5 (2•0--7•5)2•0 (1•0--3•0)0•0079Corticosteroids667 (32•63%)206 (18•95%)237 (34•40%)224 (83•58%)\<0•001  Duration of use, days7•0 (4•0--12•0)8•0 (5•0--12•0)8•0 (5•0--13•0)5•0 (3•0--10•0)0•0001Intravenous immunoglobin468 (22•90%)176 (16•19%)144 (20•90%)148 (55•22%)\<0•001High-flow nasal cannula oxygen therapy75/1705 (4•40%)20/809 (2•47%)44/628 (7•01%)11 (4•10%)\<0•001Non-invasive mechanical ventilation117/1705 (6•86%)0/809 (0•00%)0/628 (0•00%)117 (43•66%)\< 0•001Invasive mechanical ventilation/ECMO129/1705 (7•57%)0/809 (0•00%)1/628 (0•16%)128 (47•76%)\<0•001OutcomesThe highest SOFA Score1•0 (0•0--2•0)0•0 (0•0--1•0)1•0 (1•0--2•0)14•0 (12•0--17•0)0•0001 0--11321 (64•63%)968 (89•05%)353 (51•23%)0 (0•00%)\<0•001 2--3385 (18•84%)96 (8•83%)272 (39•48%)17 (6•34%)②‥ ≥4338 (16•54%)23 (2•12%)64 (9•29%)251 (93•66%)‥Acute liver injury773 (37•82%)330 (30•36%)301 (43•69%)142 (52•99%)\<0•001Sepsis711 (34•78%)110 (10•12%)333 (48•33%)268 (100•00%)\<0•001Hypoproteinaemia474/2041 (23•22%)103/1085 (9•49%)173/688 (25•15%)198 (73•88%)\<0•001ARDS446 (21•82%)29 (2•67%)149 (21•63%)268 (100•00%)\<0•001Acute cardiac injury309/1831 (16•88%)45/940 (4•79%)72/635 (11•34%)192/256 (75•00%)\<0•001Respiratory failure273 (13•36%)5 (0•46%)13 (1•89%)255 (95•15%)\<0•001Acute kidney injury250 (12•23%)63 (5•80%)59 (8•56%)128 (47•76%)\<0•001Coagulopathy243 (11•89%)42 (3•86%)45 (6•53%)156 (58•21%)\<0•001Septic shock242 (11•84%)4 (0•37%)8 (1•16%)230 (85•82%)\<0•001Admission to ICU163 (7•97%)5 (0•46%)3 (0•44%)155 (57•84%)\<0•001Heart failure134/2041 (6•57%)6/1086 (0•55%)7/688 (1•02%)121/267 (45•32%)\<0•001Secondary infection27 (1•32%)1 (0•09%)6 (0•87%)20 (7•46%)\<0•001Time from illness onset to ICU admission, days15•0 (11•0--22•0)25•0 (14•0--27•0)12•5 (12•0--13•0)15•0 (11•0--22•0)0•5010ICU length of stay, days7•0 (3•0--11•0)7•0 (1•0--12•0)13•0 (9•0--27•0)7•0 (3•0--11•0)0•1847Time from illness onset to death or discharge, days34•0 (26•0--42•0)34•0 (27•0--43•0)36•0 (29•0--43•0)24•0 (17•0--35•0)0•0001Hospital length of stay of survivors, days20•0 (14•0--28•0)18•0 (12•0--25•0)23•0 (17•0--30•0)32•0 (27•0--38•0)0•0001Hospital length of stay of non-survivors, days9•0 (5•0--16•0)8•0 (1•0--15•0)9•0 (8•0--13•5)9•0 (5•0--16•0)0•8011Duration of viral shedding after COVID-19 onset, days24•0 (19•0--31•0)24•0 (19•0--32•0)24•0 (19•0--30•0)23•0 (19•0--30•5)0•8407Non-survivors235 (11•50%)2 (0•18%)4 (0•58%)229 (85•45%)\<0•001[^3]

The median value of the highest SOFA score in clinical course was dramatically higher in critical group than in severe and moderate groups (critical vs. severe vs. moderate: 14•0 vs. 1•0 vs. 0•0; [Table 2](#tbl0002){ref-type="table"}). Critical group exhibited a higher risk to develop multi-organ damage including sepsis (100%), ARDS (100%), respiratory failure (95•15%), and septic shock (85•82%), resulting in more admission to ICU (57•84%) and more death (85•45%). Longer hospital stays of survivors, shorter hospital stays and time from illness onset to death or discharge were observed in critical group. Moreover, the median duration of viral shedding was 24 days, being comparable in three groups. The three longest duration of viral shedding in all patients were 76, 70, and 51 days since symptom onset. The top three duration of positive SARS-CoV-2 RNA were 46, 43, and 43 days. Basic information of patients admitted to ICU and general wards taken over by different medical teams are shown in Supplementary Tables 1 and 2, respectively.

3.4. Risk factors associated with disease severity {#sec0014}
--------------------------------------------------

The severity of disease climbed up straightly with age (Supplementary Figure 2A). On the other hand, males of all ages had significantly higher proportion of more serious diseases than females, with overall *P* \< 0•05 (chi-square test) for all age groups (Supplementary Figure 2A). The odds ratios comparing male to female were 2•24 (95% CI: 1•70--2•96; *P* \< 0•001) for critical illness and 1•61 (95% CI: 1•34--1•93; *P* \< 0•001) for severe/critical illness after adjusting for ages (Supplementary Figure 2B and 2C). Interestingly, we found that sex was an effect modifier for hypertension and CHD. In univariable analysis, hypertension (OR:2•76, 95% CI: 1•97--3•86, *P* \< 0•001) and CHD (OR:2•75, 95% CI: 1•76--4•29, *P* \< 0•001) were remarkable risk factors in male patients, but they did not affect the odds of developing into critical illness in female (OR:1•42, 95% CI: 0•92--2•18, *P* = 0•113; OR:1•40, 95% CI: 0•72--2•73, *P* = 0•001). In our study population, males with hypertension had an increased proportion of critical illness across ages ([Fig. 4](#fig0004){ref-type="fig"} A). Patients with hypertension or CHD had an increased probability to develop into critical or severe/critical diseases only in male but not in female ([Fig. 4](#fig0004){ref-type="fig"}B and [4](#fig0004){ref-type="fig"}C). The significant differences of ORs for hypertension and CHD between different sexes were further confirmed using logistic regression models containing the interaction terms (sex and hypertension, sex and CHD, [Table 3](#tbl0003){ref-type="table"} ). As a result, a single model that combined male and female is inappropriate, so we reported models based on different sexes separately ([Table 3](#tbl0003){ref-type="table"} and Supplementary Table 3).Fig. 4Different effects of hypertension and CHD in male and female patients with COVID-19.A. The proportions of critical disease in male and female patients with or without hypertension in different age groups were shown. B. The probabilities of developing into critical or severe/critical disease were predicted using logistic regression models containing age, gender, hypertension, and the interaction term of gender and hypertension. Age-adjusted *P* values for hypertension in different genders were shown. C. The probabilities of developing into critical or severe/critical disease were predicted using logistic regression models containing age, gender, CHD, and the interaction term of gender and CHD. Age-adjusted *P* values for CHD in different genders were shown. COVID-19=coronavirus disease 2019. CHD=coronary heart disease.Fig. 4:Table 3Risk factors associated with critical disease (vs. moderate and severe disease).Table 3Univariable AnalysisMultivariable AnalysisMaleFemaleMaleFemaleOR (95% CI)*p* valueOR (95% CI)*p* valueEffect modification *p* value^a^OR (95% CI)*p* valueOR (95% CI)*p* valueFactors with effect modificationHypertension2•76 (1•97--3•86)\<0•0011•42 (0•92--2•18)0•1130•0072•05 (1•42--2•95)\<0•0010•90 (0•56--1•45)0•677CHD2•75 (1•76--4•29)\<0•0011•40 (0•72--2•73)0•3220•0431•65 (1•02--2•66)0•041‥‥COPD3•01 (0•97--9•32)0•05615•99 (2•64--96•99)0•0030•068‥‥11•32 (1•63--78•77)0•014CharacteristicsAge, years^b^1•06 (1•04--1•07)\<0•0011•07 (1•05--1•09)\<0•001‥‥‥‥‥ ≥508•28 (4•01--17•10)\<0•0018•93 (2•80--28•49)\<0•001‥‥‥‥‥ ≥603•41 (2•31--5•02)\<0•0013•78 (2•17--6•58)\<0•001‥2•63 (1•76--3•95)\<0•0013•89 (2•17--6•95)\<0•001Presence of comorbidity4•01 (2•64--6•08)\<0•0012•40 (1•48--3•89)\<0•001‥‥‥‥‥ Diabetes1•39 (0•94--2•06)0•0981•61 (0•94--2•76)0•080‥‥‥1•32 (0•74--2•35)0•353 Tumor2•83 (1•36--5•86)0•0053•32 (1•39--7•97)0•007‥2•35 (1•09--5•08)0•0293•76 (1•50--9•41)0•005 CLD1•13 (0•54--2•38)0•7511•11 (0•33--3•73)0•864‥‥‥‥‥ CKD1•36 (0•44--4•18)0•5934•28 (1•31--13•92)0•016‥‥‥3•58 (0•98--13•06)0•054Number of comorbidities^b^1•83 (1•57--2•14)\<0•0011•58 (1•30--1•92)\<0•001‥‥‥‥‥Fever1•02 (0•64--1•63)0•9201•08 (0•65--1•80)0•754‥‥‥‥‥ Temperature, °C^b^1•03 (0•87--1•22)0•6981•07 (0•86--1•33)0•566‥‥‥‥‥ Temp(max)≥39 °C0•85 (0•59--1•23)0•3890•86 (0•50--1•50)0•601‥‥‥‥‥Cough1•63 (1•09--2•44)0•0181•63 (0•96--2•78)0•073‥1•70 (1•12--2•59)0•0131•54 (0•89--2•65)0•122Sputum1•28 (0•92--1•78)0•1421•07 (0•69--1•66)0•756‥‥‥‥‥Vomiting1•18 (0•54--2•62)0•6760•84 (0•30--2•37)0•738‥‥‥‥‥Diarrhea0•96 (0•64--1•42)0•8261•04 (0•64--1•69)0•875‥‥‥‥‥Fatigue1•36 (0•97--1•89)0•0741•11 (0•72--1•73)0•630‥‥‥‥‥Myalgia0•87 (0•57--1•32)0•5030•88 (0•51--1•53)0•662‥‥‥‥‥[^4]

In univariable analysis, cough (OR:1•63, 95% CI: 1•09--2•44, *P* = 0•018) in addition to hypertension (OR:2•76, 95% CI: 1•97--3•86, *P* \< 0•001) and CHD (OR:2•75, 95% CI: 1•76--4•29, *P* \< 0•001) were associated with critical illness in male. COPD (OR:15•99, 95% CI: 2•64--96•99, *P* = 0•003) and CKD (OR:4•28, 95% CI: 1•31--13•92, *P* = 0•016) were associated with critical illness in female. While age, tumor, the presence of comorbidity, and number of comorbidities were associated with critical illness in both male and female patients. In multivariable analysis of critical illness, we found that hypertension (OR:2•05, 95% CI: 1•42--2•95, *P* \< 0•001), CHD (OR:1•65, 95% CI: 1•02--2•66, *P* = 0•041), tumor (OR:2•35, 95% CI: 1•09--5•08, *P* = 0•029), age ≥ 60 years (OR:2•63, 95% CI: 1•76--3•95, *P* \< 0•001), and cough (OR:1•70, 95% CI: 1•12--2•59, *P* = 0•013) were independent risk factors for male patients, and COPD (OR:11•32, 95% CI: 1•63--78•77, *P* = 0•014), tumor (OR:3•76, 95% CI: 1•50--9•41, *P* = 0•005), and age ≥ 60 years (OR:3•89, 95% CI: 2•17--6•95, *P* \< 0•001) were independent risk factors for female patients. Additionally, CKD reached marginally significant (OR=3•58, 95% CI: 0•98--13•06, *P* = 0•054) in multivariable analysis for female. Cough, however, can be caused by many different conditions, including COPD, heart failure, ACEI side effect, and COVID-19 itself, etc. In analysis of critical illness in male, cough was no longer a statistically significant risk factor after adjusting for heart failure (OR=1•52, 95% CI: 0•92--2•50, *P* = 0•099). Therefore, cough was not yet considered to be an independent risk factor for developing critical cases. Risk factors of developing into severe/critical illness were showed in Supplementary Table 4 and 5.

4. Discussion {#sec0015}
=============

To our knowledge, this report is the largest multi-center, retrospective cohort study that comprehensively describes the clinical features of COVID-19. Meanwhile, it is the first study that elucidates the disparity of risk factors of developing severe/critical diseases between sexes. Via analyzing clinical data of 2044 adult inpatients with definite outcomes, we discovered that gender was an effect modifier for hypertension and coronary heart disease (CHD), where hypertension and CHD remarkably increased the risk of critical disease in male, but barely affected female patients.

In accordance with previous descriptions, clinical features and course of COVID-19 were similar between moderate group and severe group \[[@bib0018],[@bib0019]\]. For critical group, patients exhibited dramatically distinct features characterized by higher proportion of dyspnea and disorders of consciousness, persistent SOFA score ≥ 4, systemic organ damage, and lasting inflammatory storm manifested as increased IL-6, CRP, [d]{.smallcaps}-dimer, cTnI, leukocyte count, and decreased lymphocyte count. We observed a higher mortality for critical patients in this study than previous report (85•45% vs. 78•00%) [@bib0013], which may attribute to delayed access to medical care in the peak of outbreak in Wuhan, the epicenter of COVID-19 crisis in China, and definition of COVID-19 severity as the most severe condition during the entire course of the disease. We enrolled discharged/dead patients including patients with critical illness on admission and those deteriorating into critical diseases. Noticeably, severe patients had lower mortality than previously reported (0•58% vs. 22•00%) [@bib0013]. We owed this to contributions of numerous experts that rushed to Wuhan from the whole country, which represents the highest level of critical care in China.

Critical group experienced more multiorgan damage including ARDS, sepsis, coagulopathy, and acute liver, kidney, and cardiac injury. The underlying mechanisms for SARS-CoV-2-related multiorgan damage remain unclear. Angiotensin-converting enzyme 2 (ACE2) gene is broadly expressed in lung alveolar cells, vascular endothelial cells, kidneys, heart, and other tissues [@bib0020]. The multiorgan damage was partially induced by direct attack of SARS-CoV-2. ^21^Meanwhile, this and previous studies observed significantly higher levels of pro-inflammatory cytokines and chemokines including IL-2R, IL-6, IL-8, IL-10, and TNF-α in critical group \[[@bib0007],[@bib0020],[@bib0021]\]. Innate and adaptive immune responses were activated after virus infection, dysregulation of which could result in cytokine release syndrome (CRS) and subsequent multi-organ damage, even death \[[@bib0021],[@bib0022]\]. CRS was more prevalently seen in critical group. Immunosuppression therapies such as tocilizumab and glucocorticoids were recommended for patients with grade 3 or 4 CRS, where tocilizumab, an anti-human IL-6R mAb, specifically inhibits IL-6 signaling, and corticosteroids have more widespread effects on immune system [@bib0023]. Whether direct attacks of SARS-CoV-2 or CRS or a combination of both lead to multiorgan damage is still unclear. However, exploration of the underlying causes of multiorgan damage is crucial because they determined the clinical decision-making of treatment to attenuate multiorgan damage.

Advanced age and male sex had been reported as risk factors of mortality in SARS, MERS, and COVID-19 \[[@bib0012],[@bib0013],[@bib0024]\]. Here, we reported that advanced age was highly associated with critical disease in COVID-19 patients. More importantly, we found that the effects of multiple critical factors on COVID-19 progression were completely different between sexes. Hypertension and CHD dramatically increased the risk of critical disease in male, but barely affected female patients. COPD and CKD seemed more likely to affect females than males. However, hypertension and CHD have much higher prevalence rates than COPD and CKD, which might be a basic reason for more cases of serious COVID-19 in males. Sex differences were also reported in hypertension with depressive order and coronary artery disease \[[@bib0025],[@bib0026]\], which represented that male had a higher risk of suffering from hypertension beyond protective role of estrogens [@bib0027]. Meantime, female smokers had accelerated decline in forced expiratory volume in one second (FEV1), who were more vulnerable to COPD and had a high risk of hospitalization and death with age \[[@bib0028],[@bib0029]\]. ACE2 polymorphism, androgen mediated SARS-CoV-2 infection, and estrogen protective role might also account for sex differences [@bib0030], [@bib0031], [@bib0032]. Similar trend in sex differences were observed in certain reports of SARS and MERS, albeit poorly investigated [@bib0024].

The prevalence of COPD in this study was only 0.88%. Guan WJ, et al. reported 1.8% (24/1566) COVID-19 patients with COPD, while the data were extracted from 575 hospitals in 31 province/autonomous regions/provincial municipalities across mainland China [@bib0004]. It was reported that the prevalence of COPD differed by geographic region, with the lowest in central China, where Wuhan loacted [@bib0033]. Therefore, even if COPD is a risk factor for critical disease of female COVID-19 patients, it will not be of great importance in the present study, considering the low prevalence of COPD in female.

This study has some limitations. First, though data used for analysis are comprehensive, a few patients did not receive all above-mentioned laboratory tests, and several information such as symptoms and comorbidities are documented in accordance with personal narratives. For instance, patient outcomes could be different with the different frequency and severity, chronic and acute onset of cough, which was not clear. Second, COVID-19 cases with comorbidities such as COPD and CKD are limited. Further investigations including more COVID-19 patients with comorbidities will consolidate our findings. Third, patients in our study are primarily locals in Wuhan. Larger nationwide or worldwide cohort studies are needed to support our results.

In summary, this multi-center retrospective cohort study provides comprehensive front-line information about different severity of COVID-19 and insights into the different risks associated with developing into serious disease. The fundamental differences in disease progression between sexes highlight the importance of dividing sexes in clinical and epidemiologic works, because it might be inappropriate to combine males and female as one single population. These findings also highlight the importance in further investigating the molecular and genetic mechanism underlying the differences between sexes to understand the nature of the disease, and perhaps other coronavirus appearing in future.

Declaration of Competing Interest
=================================

We declare no conflicts of interests for all authors.

Appendix. Supplementary materials {#sec0021}
=================================

Image, application 1 Image, application 2

Contributors {#sec0016}
============

DL, PC, SZ, SW, XF, YG, and SX contributed equally to this work. SZ, SW, YG, SX, RY, YW, and YY collected the clinical data. RL, XJ, JC, JL, YY, XZ, CS, NJ, WG, XL and GC double-checked and loaded the data into database. DL, PC, XF, CL, and QG analyzed the clinical records. PC, SZ, SW, XF, YG, SX, and HL drafted the manuscript. DL, QG, PC, SZ, SW, XF, YG, and SX analyzed and interpreted the data. CL advised on the conception and design of the study. DL and QG conceptualized and designed the study, supervised the project, and revised the manuscript. All authors vouch for the respective data and analysis, revised, approved the final version, and agreed to publish the manuscript.

Acknowledgments {#sec0017}
===============

We thank all health-care workers and people involved in fighting against COVID-19.

Funding {#sec0018}
=======

The study was supported by the National Science and Technology Major Sub-Project (2018ZX10301402--002), the Technical Innovation Special Project of Hubei Province (2018ACA138), the National Natural Science Foundation of China (81772787, 81873452, and 81974405), and the Fundamental Research Funds for the Central Universities (2019kfyXMBZ024).

Data sharing statement {#sec0019}
======================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary material associated with this article can be found in the online version at doi:[10.1016/j.eclinm.2020.100471](https://doi.org/10.1016/j.eclinm.2020.100471){#interref0001}.

[^1]: These authors contributed equally.
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[^3]: Data are median (IQR), n (%) or n/N (%). *p* values were calculated by Kruskal-Wallis test, χ² test or Fisher\'s exact test, as appropriate. ECMO=extracorporeal membrane oxygenation. SOFA=Sequential Organ Failure Assessment. ARDS=acute respiratory distress syndrome. ICU=intensive care unit. COVID-19=coronavirus disease 2019. Interferon, indicating Recombinant Human Interferon α−2b inhalation or Interferon α−1b inhalation.

[^4]: OR=odds ratio. CI=confidence interval. CHD=coronary heart disease. COPD=chronic obstructive pulmonary disease. CLD=chronic liver disease. CKD=chronic kidney disease. ^a^ Test of effect modification between gender and other factors using logistic regression models containing the interaction terms (gender and hypertension, gender and CHD, gender and COPD). ^b^ Per 1 unit increase.
